Is ETTX or RYLD a better dividend investment in 2026?

ETTX currently yields 91.32% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: ETTX offers higher current income.

What is the dividend yield difference between ETTX and RYLD?

ETTX has a forward dividend yield of 91.32% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 79.18 percentage points.

Home › Compare › ETTX vs RYLD

ETTX vs RYLD: Dividend Comparison 2026

ETTX yields 91.32% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ETTX wins by $2.67M in total portfolio value

INVESTMENT

TIME HORIZON10 years

ETTX

● Live price

91.32%

Share price

$2.19

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.71M

Annual income

$860,660.59

Full ETTX calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — ETTX vs RYLD

📍 ETTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ETTX	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ETTX + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ETTX pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ETTX

Annual income on $10K today (after 15% tax)

$7,762.56/yr

After 10yr DRIP, annual income (after tax)

$731,561.50/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, ETTX beats the other by $729,362.25/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ETTX + RYLD for your $10,000?

ETTX: 50%RYLD: 50%

100% RYLD50/50100% ETTX

Portfolio after 10yr

$1.38M

Annual income

$431,623.97/yr

Blended yield

31.29%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on ETTX right now

ETTX

Analyst Ratings

Buy

Hold

Consensus: Buy

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ETTX buys

RYLD buys

No recent congressional trades found for ETTX or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricETTXRYLD

Forward yield	91.32% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$2.71M	$44.5K ✓
Annual income after 10y	$860,660.59 ✓	$2,587.35
Total dividends collected	$2.40M	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: ETTX vs RYLD ($10,000, DRIP)

Year	ETTX Portfolio	ETTX Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$19,832	$9,132.42	$11,914	$1,213.65	+$7.9K → ETTX
2	$38,148	$16,926.92	$14,099	$1,351.30	+$24.0K → ETTX
3	$71,247	$30,428.85	$16,580	$1,494.55	+$54.7K → ETTX
4	$129,347	$53,112.88	$19,384	$1,642.61	+$110.0K → ETTX
5	$228,518	$90,117.05	$22,535	$1,794.70	+$206.0K → ETTX
6	$393,309	$148,794.86	$26,063	$1,950.00	+$367.2K → ETTX
7	$660,182	$239,341.26	$29,995	$2,107.69	+$630.2K → ETTX
8	$1,081,855	$375,459.71	$34,361	$2,266.99	+$1.05M → ETTX
9	$1,732,607	$575,022.24	$39,194	$2,427.12	+$1.69M → ETTX
10	$2,714,550	$860,660.59	$44,525	$2,587.35	+$2.67M → ETTX

ETTX vs RYLD: Complete Analysis 2026

ETTX — Stock

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Full ETTX Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this ETTX vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ETTX vs SCHD ETTX vs JEPI ETTX vs O ETTX vs KO ETTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.